Jump to main content
Jump to site search

Issue 42, 2013
Previous Article Next Article

Tumour targeting with radiometals for diagnosis and therapy

Author affiliations


Use of radiometals in nuclear oncology is a rapidly growing field and encompasses a broad spectrum of radiotracers for imaging via PET (positron emission tomography) or SPECT (single-photon emission computed tomography) and therapy via α, β, or Auger electron emission. This feature article opens with a brief introduction to the imaging and therapy modalities exploited in nuclear medicine, followed by a discussion of the multi-component strategy used in radiopharmaceutical development, known as the bifunctional chelate (BFC) method. The modular assembly is dissected into its individual components and each is discussed separately. The concepts and knowledge unique to metal-based designs are outlined, giving insight into how these radiopharmaceuticals are evaluated for use in vivo. Imaging nuclides 64Cu, 68Ga, 86Y, 89Zr, and 111In, and therapeutic nuclides 90Y, 177Lu, 225Ac, 213Bi, 188Re, and 212Pb will be the focus herein. Finally, key examples have been extracted from the literature to give the reader a sense of breadth of the field.

Graphical abstract: Tumour targeting with radiometals for diagnosis and therapy

Back to tab navigation

Publication details

The article was received on 28 Feb 2013, accepted on 27 Mar 2013 and first published on 02 Apr 2013

Article type: Feature Article
DOI: 10.1039/C3CC41554F
Citation: Chem. Commun., 2013,49, 4720-4739
  •   Request permissions

    Tumour targeting with radiometals for diagnosis and therapy

    C. F. Ramogida and C. Orvig, Chem. Commun., 2013, 49, 4720
    DOI: 10.1039/C3CC41554F

Search articles by author